GDC-0068, also known as Ipatasertib or RG-7440, is a small molecule inhibitor that has been developed for the treatment of cancer. This compound has gained attention for its potential to inhibit the growth and survival of cancer cells, particularly in breast and prostate cancers.
Chemical Name: N-[4-methyl-5-[2-(2-pyridinyl)ethoxy]-1H-benzimidazol-2-yl]-3-(trifluoromethyl)benzenesulfonamide
Molecular formula: C23H19F3N4O3S
Formula weight: 500.48 g/mol
CAS No: 1001264-89-6
Top Ten Keywords from Google and Synonyms:
Synonyms: GDC-0068, Ipatasertib, RG-7440, GDC0068, RG7440, 1001264-89-6
Health Benefits of this Product: The health benefits of GDC-0068 are primarily related to its potential as a cancer therapy. Research has shown that the compound can inhibit the growth and survival of cancer cells by targeting the PI3K/AKT/mTOR pathway, which is commonly activated in many types of cancer. In clinical trials, GDC-0068 has demonstrated promising results as a treatment for advanced breast and prostate cancers.
Potential Effects: GDC-0068 has the potential to be an effective cancer therapy due to its ability to inhibit the PI3K/AKT/mTOR pathway. This pathway is involved in regulating numerous cellular processes that are necessary for tumor growth and survival, including cell proliferation, angiogenesis, and apoptosis resistance. By inhibiting this pathway, GDC-0068 can slow or stop the growth of cancer cells and potentially lead to their destruction.
Product Mechanism: GDC-0068 works by inhibiting AKT, a protein kinase that is downstream of the PI3K/AKT/mTOR pathway and plays a key role in promoting cancer cell survival and growth. By inhibiting AKT, GDC-0068 disrupts the signaling pathways that allow cancer cells to survive and proliferate. Additionally, GDC-0068 has been shown to inhibit mTORC1, another component of the PI3K/AKT/mTOR pathway that is important for regulating cell metabolism and growth.
Safety: As with any experimental drug, the safety of GDC-0068 is still being studied. However, initial studies have indicated that the compound is generally well-tolerated in patients and does not cause significant toxicity or adverse side effects at therapeutic doses. Further studies will be necessary to fully evaluate the safety profile of this compound in larger patient populations over longer periods of time.
Side Effects: At present, there is limited information available about the potential side effects of GDC-0068. However, like other cancer therapies, it is possible that the compound could cause some adverse effects such as nausea, fatigue, and decreased immune function. Future studies will be needed to determine the full range of potential side effects associated with this compound.
Dosing Information: The optimal dosing of GDC-0068 for human patients has not yet been fully established, as the compound is still undergoing clinical trials. However, early studies have used doses ranging from 200 to 600 mg once daily, depending on the specific type of cancer being treated. It is likely that future clinical trials will investigate various dosing regimens to determine the most effective and safe dose for treating cancer in humans.
Conclusion: GDC-0068 is a promising small molecule inhibitor that has shown potential as a cancer therapy, particularly in breast and prostate cancers. Its ability to inhibit the PI3K/AKT/mTOR pathway makes it an attractive target for drug development, and early clinical trials have demonstrated promising results. While more studies are needed to determine the safety and efficacy of this compound, initial results suggest that GDC-0068 could be an important tool in the fight against cancer